Central Nervous System Tumors Clinical Trial
Official title:
A Phase I Study Of Irinotecan and Bevacizumab With Temozolomide in Children With Recurrent/Refractory Central Nervous System Tumors
Bevacizumab, irinotecan, and temozolomide are three agents shown to have promising activity in a variety of central nervous system tumors. No prospective studies have been published or are currently in progress within the major consortiums with this combination of drugs. Brain tumors are the second most common cause of cancer in pediatrics and the leading cause of cancer death in children. For children with High Grade Gliomas or with relapsed/refractory brain tumors, new agents in new combinations are needed. Historical data shows that newly diagnosed high grade gliomas 5 year progression free survival is 28-42%. Recurrent malignant gliomas median survival is 3-9 months. Recurrent medulloblastoma's 2 years survival is 9%. This study is a phase I study designed to provide an objective observation of toxicity and establish a maximum tolerated dose of this combination. In addition, this study will observe the response of children with relapsed or refractory central nervous system tumors.
Bevacizumab dosing is 10 mg/kg on day 1 and day 15 of a 28 days course given IV. Irinotecan dosing is 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the MTD of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150 mg/m2. For dose level 0 Temozolomide, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO. Doses will be escalated according to standard phase I dose escalation criteria. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00003935 -
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
|
Phase 1 | |
| Terminated |
NCT00107471 -
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
|
Phase 1/Phase 2 | |
| Completed |
NCT00003573 -
Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
|
Phase 2 | |
| Recruiting |
NCT05235074 -
OH2 Oncolytic Viral Therapy in Central Nervous System Tumors
|
Phase 1/Phase 2 | |
| Suspended |
NCT05308407 -
POWER UP: Participating Online While Exercising to Recover Using Play
|
N/A | |
| Terminated |
NCT00477503 -
Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA
|
Phase 1 | |
| Active, not recruiting |
NCT01985451 -
Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）
|
Phase 2 | |
| Withdrawn |
NCT00109798 -
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
|
N/A | |
| Completed |
NCT00003203 -
Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors
|
Phase 2 | |
| Completed |
NCT00003141 -
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
|
Phase 1 | |
| Completed |
NCT02462629 -
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT01735747 -
Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma
|
Phase 2 | |
| Recruiting |
NCT00607984 -
Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors
|
N/A | |
| Completed |
NCT00899834 -
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
|
N/A | |
| Completed |
NCT00066248 -
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
|
Phase 2 | |
| Completed |
NCT00187226 -
A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects
|
Phase 2 | |
| Completed |
NCT02793466 -
Durvalumab in Pediatric and Adolescent Patients
|
Phase 1 | |
| Withdrawn |
NCT01052363 -
OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas
|
Phase 1 | |
| Completed |
NCT00047320 -
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
|
Phase 2 | |
| Completed |
NCT00945828 -
Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors
|
N/A |